Oral Therapies for Peyronie's Disease
Colchicine is a drug most known for its treatment of acute gout attacks. But it has also been used to treat Peyronie’s Disease (PD) due to its anti-inflammatory and anti-fibrotic properties. One of the problems with PD is the build-up of excessive fibrous connective tissue in the penis which leads to scarring and penile curvature (PC).
An uncontrolled trial involving 24 men with PD showed that colchicine resolved penile pain in 78% of case, plaque size in 50% and Penile Curvature (PC) in 38% of cases.
In another more recent uncontrolled study with 60 patient’s colchicine was able to improve pain in 95% and penile deformity in 30% of cases.
However, further studies where a placebo controlled group were also studied showed little improvement in PD and concluded that four months of therapy with up to 2.5 mg colchicine daily in patients with PD, had no beneficial effect.
Carnitine is an inhibitor of acetyl coenzyme-A that allows for the decrease of free radical formation during times of cell stress.
It has been reported that carnitine may control fibroblast proliferation and collagen production thereby reducing penile fibrosis. One study compared the effects of carnitine with tamoxifen and after three months showed that carnitine was significantly more effective than tamoxifen in reducing pain and PC and in inhibiting disease progression, but not in reducing penile plaque size.
However, no placebo controlled studies into the effects of carnitine on PD are available at the moment.
Pentoxifylline is another oral therapy thought to have anti-inflammatory and antifibrogenic properties. It had been widely used to treat other fibrotic disorders, before research into its use to treat PD took place.
Although no placebo controlled studies have taken place research has shown that pentoxifylline was able to stabilize or decrease calcium content in PD plaque. Further studies into its use in combination with verapamil, or vitamin E and topical diclofenac (applied twice daily) resulted in better outcomes.
Research into the use of Oral Therapies for Peyronie’s Disease can be found by following this link.